Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
CA: A Cancer Journal for Clinicians · 2023-11 · 73 (6) · 620-652
DOI: 10.3322/caac.21785 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 17.06.2023. Verfasst von Zsolt Megyesfalvi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Biological Products. Die Arbeit wurde bisher 329-mal zitiert (Crossref) und nennt 316 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1 , and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative‐intent lung resection, and these individuals require adjuvant platinum‐etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum‐etoposide chemotherapy. Patients with metastatic (extensive‐stage) disease are treated with a combination of platinum‐etoposide chemotherapy plus immunotherapy with an anti‐programmed death‐ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum‐based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary.
- National Koranyi Institute of Pulmonology, Budapest, Hungary.
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
- Department of Medicine I, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Balazs Dome
Zitieren
APA
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., Bunn, P. A., Renyi-Vamos, F., Schelch, K., Prosch, H., Byers, L. A., Hirsch, F. R., & Dome, B. (2023). Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73(6), 620-652. https://doi.org/10.3322/caac.21785
Vancouver
Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians. 2023;73(6):620-652. doi:10.3322/caac.21785
BibTeX
@article{Megyesfalvi2023,
author = {Megyesfalvi, Zsolt and Gay, Carl M and Popper, Helmut and Pirker, Robert and Ostoros, Gyula and Heeke, Simon and Lang, Christian and Hoetzenecker, Konrad and Schwendenwein, Anna and Boettiger, Kristiina and Bunn, Paul A and Renyi-Vamos, Ferenc and Schelch, Karin and Prosch, Helmut and Byers, Lauren A and Hirsch, Fred R and Dome, Balazs},
title = {Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions},
journal = {CA: A Cancer Journal for Clinicians},
year = {2023},
volume = {73},
number = {6},
pages = {620--652},
doi = {10.3322/caac.21785}
}
EUVIMED